Compare PulteGroup, Inc. (PHM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Revvity Inc — how do they compare? PulteGroup, Inc. trades at $111.21 (market cap $21.63B), while Revvity Inc trades at $154.6 (market cap $16.98B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays the higher dividend (0.92%). Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Revvity Inc for 12 Days on average.
| PHM | RVTY | |
|---|---|---|
Market Cap | $21.63B | $16.98B |
Volume | 2,324,729 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $157.36 |
52-Week Low | $110.11 | $82.26 |
Typical Hold Time | 91 Days | 12 Days |
Enterprise Value | $22.04B | $19.30B |
Dividend Yield | 0.92% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector weakness driven by rising mortgage rates. The stock shows bearish technical signals with key support at $110, while fundamentals reveal solid profitability with 11.62% net margin and attractive valuation at P/E of 11.6. Recent earnings show mixed results with Q2 beat but Q4 and Q1 misses, with Q3 results pending. The company maintains strong cash flow generation with $355M net cash flow in 2025.
PHM presents a value opportunity with below-market valuation and consistent profitability, though near-term headwinds from rising rates pressure housing demand. Analyst consensus targets $139.80 (24% upside) with 45% buy ratings, but technical weakness and macroeconomic risks require careful monitoring. The dividend yield provides income support during market volatility.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
